Background: Peripheral T cell lymphoma (PTCL) is a heterogeneous entity with poor survival. We evaluated the neutrophil-to-lymphocyte ratio (NLR), absolute lymphocyte count (ALC), and platelet count as new prognostic factors for PTCL. Patients and Methods: We retrospectively analyzed 77 patients with PTCL initially treated with anthracycline-based chemotherapy. Survival curves were compared between groups with different initial NLR (iNLR), end-point NLR (eNLR), initial ALC, and platelet counts. Cox regression was used to analyze the risk factor for survival. Results: Patients with a higher eNLR (≥3), lymphopenia (< 1,000/μL), and thrombocytopenia (< 150 K/μL) had an inferior progression-free survival (PFS) and overall survival (OS) compared to their counterparts, while a higher iNLR (≥3) was predictive of a shorter OS but not PFS. Among these, thrombocytopenia was an independent poor prognostic factor for both PFS and OS, with a hazard ratio of 2.42 (p = 0.012) for PFS and 4.21 (p = 0.006) for OS. The presence of thrombocytopenia further stratified patients with a worse prognosis within overlapping risk-groups by the prognostic index for PTCL. Conclusions: Our study showed that thrombocytopenia at diagnosis was an independent prognostic factor for survival in patients with PTCL.

1.
Swerdlow
SH
,
Campo
E
,
Pileri
SA
,
Harris
NL
,
Stein
H
,
Siebert
R
, et al.
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
.
Blood
.
2016
May
;
127
(
20
):
2375
90
.
[PubMed]
0006-4971
2.
Anderson
JR
,
Armitage
JO
,
Weisenburger
DD
.
Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project
.
Ann Oncol
.
1998
Jul
;
9
(
7
):
717
20
.
[PubMed]
0923-7534
3.
Vose
J
,
Armitage
J
,
Weisenburger
D
;
International T-Cell Lymphoma Project
.
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes
.
J Clin Oncol
.
2008
Sep
;
26
(
25
):
4124
30
.
[PubMed]
0732-183X
4.
Armitage
JO
,
Vose
JM
,
Weisenburger
DD
.
Towards understanding the peripheral T-cell lymphomas
.
Ann Oncol
.
2004
Oct
;
15
(
10
):
1447
9
.
[PubMed]
0923-7534
5.
Foss
FM
,
Zinzani
PL
,
Vose
JM
,
Gascoyne
RD
,
Rosen
ST
,
Tobinai
K
.
Peripheral T-cell lymphoma
.
Blood
.
2011
Jun
;
117
(
25
):
6756
67
.
[PubMed]
0006-4971
6.
International Non-Hodgkin’s Lymphoma Prognostic Factors Project
.
A predictive model for aggressive non-Hodgkin’s lymphoma
.
N Engl J Med
.
1993
Sep
;
329
(
14
):
987
94
.
[PubMed]
0028-4793
7.
Gallamini
A
,
Stelitano
C
,
Calvi
R
,
Bellei
M
,
Mattei
D
,
Vitolo
U
, et al.;
Intergruppo Italiano Linfomi
.
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study
.
Blood
.
2004
Apr
;
103
(
7
):
2474
9
.
[PubMed]
0006-4971
8.
Gutiérrez-García
G
,
García-Herrera
A
,
Cardesa
T
,
Martínez
A
,
Villamor
N
,
Ghita
G
, et al.
Comparison of four prognostic scores in peripheral T-cell lymphoma
.
Ann Oncol
.
2011
Feb
;
22
(
2
):
397
404
.
[PubMed]
0923-7534
9.
Porrata
LF
,
Ristow
K
,
Habermann
T
,
Inwards
DJ
,
Micallef
IN
,
Markovic
SN
.
Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio
.
Am J Hematol
.
2010
Nov
;
85
(
11
):
896
9
.
[PubMed]
0361-8609
10.
Keam
B
,
Ha
H
,
Kim
TM
,
Jeon
YK
,
Lee
SH
,
Kim
DW
, et al.
Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
.
Leuk Lymphoma
.
2015
Jul
;
56
(
7
):
2032
8
.
[PubMed]
1042-8194
11.
Templeton
AJ
,
McNamara
MG
,
Šeruga
B
,
Vera-Badillo
FE
,
Aneja
P
,
Ocaña
A
, et al.
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis
.
J Natl Cancer Inst
.
2014
May
;
106
(
6
):
dju124
.
[PubMed]
0027-8874
12.
Beltran
BE
,
Aguilar
C
,
Quiñones
P
,
Morales
D
,
Chavez
JC
,
Sotomayor
EM
, et al.
The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified
.
Leuk Lymphoma
.
2016
;
57
(
1
):
58
62
.
[PubMed]
1042-8194
13.
Chua
W
,
Charles
KA
,
Baracos
VE
,
Clarke
SJ
.
Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer
.
Br J Cancer
.
2011
Apr
;
104
(
8
):
1288
95
.
[PubMed]
0007-0920
14.
Ray-Coquard
I
,
Cropet
C
,
Van Glabbeke
M
,
Sebban
C
,
Le Cesne
A
,
Judson
I
, et al.;
European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
.
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas
.
Cancer Res
.
2009
Jul
;
69
(
13
):
5383
91
.
[PubMed]
0008-5472
15.
Huang
JJ
,
Jiang
WQ
,
Lin
TY
,
Huang
Y
,
Xu
RH
,
Huang
HQ
, et al.
Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type
.
Ann Oncol
.
2011
Jan
;
22
(
1
):
149
55
.
[PubMed]
0923-7534
16.
Mitrovic
Z
,
Perry
AM
,
Suzumiya
J
,
Armitage
JO
,
Au
WY
,
Coiffier
B
, et al.
The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: a study of 826 cases from the International Peripheral T-cell Lymphoma Project
.
Am J Hematol
.
2012
Aug
;
87
(
8
):
790
4
.
[PubMed]
0361-8609
17.
Castillo
JJ
,
Morales
D
,
Quinones
P
,
Cotrina
E
,
Desposorio
C
,
Beltran
B
.
Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified
.
Leuk Lymphoma
.
2010
Oct
;
51
(
10
):
1822
8
.
[PubMed]
1042-8194
18.
Vose
JM
,
Project
IP
.
International peripheral T-cell lymphoma (PTCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines
.
Blood
.
2005
;
106
:
a811
.0006-4971
19.
Cheson
BD
,
Fisher
RI
,
Barrington
SF
,
Cavalli
F
,
Schwartz
LH
,
Zucca
E
, et al.;
Alliance, Australasian Leukaemia and Lymphoma Group
;
Eastern Cooperative Oncology Group
;
European Mantle Cell Lymphoma Consortium
;
Italian Lymphoma Foundation
;
European Organisation for Research
;
Treatment of Cancer/Dutch Hemato-Oncology Group
;
Grupo Español de Médula Ósea
;
German High-Grade Lymphoma Study Group
;
German Hodgkin’s Study Group
;
Japanese Lymphorra Study Group
;
Lymphoma Study Association
;
NCIC Clinical Trials Group
;
Nordic Lymphoma Study Group
;
Southwest Oncology Group
;
United Kingdom National Cancer Research Institute
.
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
.
J Clin Oncol
.
2014
Sep
;
32
(
27
):
3059
68
.
[PubMed]
0732-183X
20.
Lin
HN
,
Liu
CY
,
Pai
JT
,
Chang
FP
,
Yang
CF
,
Yu
YB
, et al.
How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models?
Blood Cancer J
.
2012
Oct
;
2
(
10
):
e93
.
[PubMed]
2044-5385
21.
Xu
P
,
Yu
D
,
Wang
L
,
Shen
Y
,
Shen
Z
,
Zhao
W
.
Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients
.
Ann Hematol
.
2015
Feb
;
94
(
2
):
239
47
.
[PubMed]
0939-5555
22.
Chen
LP
,
Lin
SJ
,
Yu
MS
.
Prognostic value of platelet count in diffuse large B-cell lymphoma
.
Clin Lymphoma Myeloma Leuk
.
2012
Feb
;
12
(
1
):
32
7
.
[PubMed]
2152-2650
23.
Coussens
LM
,
Werb
Z
.
Inflammation and cancer
.
Nature
.
2002
Dec
;
420
(
6917
):
860
7
.
[PubMed]
0028-0836
24.
Porta
C
,
Larghi
P
,
Rimoldi
M
,
Totaro
MG
,
Allavena
P
,
Mantovani
A
, et al.
Cellular and molecular pathways linking inflammation and cancer
.
Immunobiology
.
2009
;
214
(
9-10
):
761
77
.
[PubMed]
0171-2985
25.
Kim
YR
,
Kim
JS
,
Kim
SJ
,
Jung
HA
,
Kim
SJ
,
Kim
WS
, et al.
Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy
.
J Hematol Oncol
.
2011
Aug
;
4
(
1
):
34
.
[PubMed]
1756-8722
26.
Dobbs
NA
,
Twelves
CJ
,
Gillies
H
,
James
CA
,
Harper
PG
,
Rubens
RD
.
Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry
.
Cancer Chemother Pharmacol
.
1995
;
36
(
6
):
473
6
.
[PubMed]
0344-5704
27.
Pfreundschuh
M
,
Murawski
N
,
Zeynalova
S
,
Poeschel
V
,
Reiser
M
,
Ho
AD
, et al.
Male Sex Is Associated with Lower Rituximab Trough Serum Levels and Evolves as a Significant Prognostic Factor in Elderly Patients with DLBCL Treated with R-CHOP: Results From 4 Prospective Trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL)
.
Blood
.
2009
;
114
:
1431
1431
.0006-4971
28.
Yıldırım
M
,
Kaya
V
,
Demirpençe
Ö
,
Paydaş
S
.
The role of gender in patients with diffuse large B cell lymphoma treated with rituximab-containing regimens: a meta-analysis
.
Arch Med Sci
.
2015
Aug
;
11
(
4
):
708
14
.
[PubMed]
1734-1922
29.
Carella
AM
,
de Souza
CA
,
Luminari
S
,
Marcheselli
L
,
Chiappella
A
,
di Rocco
A
, et al.
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study
.
Leuk Lymphoma
.
2013
Jan
;
54
(
1
):
53
7
.
[PubMed]
1042-8194
30.
Broccoli
A
,
Zinzani
PL
.
Peripheral T-cell lymphoma, not otherwise specified
.
Blood
.
2017
Mar
;
129
(
9
):
1103
12
.
[PubMed]
0006-4971
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.